Perioperative immunotherapy in renal cell carcinoma
Mené sur 819 patients atteints d'un carcinome rénal à haut risque (âge médian : 61 ans ; durée médiane de suivi : 30,4 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité du nivolumab en traitement néoadjuvant puis adjuvant
In The Lancet Oncology, Mohamad E Allaf and colleagues 1 report the primary results of the PROSPER trial, in which they assessed the effects of a short course of preoperative nivolumab followed by 9 months of adjuvant nivolumab compared with surgery alone in patients with high-risk (ie, clinical stage ≥T2 or any T stage and node positive) renal cell carcinoma with both clear cell and non-clear cell histology. The trial was created with a pragmatic design in agreement with patient organisations to ensure a strategy that was acceptable for both patients and clinicians, as well as the extrapolation of results to clinical practice. The study did not meet its primary endpoint, with perioperative nivolumab not showing any benefit in terms of recurrence-free survival compared with surgery alone in patients with renal cell carcinoma (hazard ratio [HR] 0·94 [95% CI 0·74–1·21]; p=0·32).
The Lancet Oncology 2023